收费全文 | 344076篇 |
免费 | 8189篇 |
国内免费 | 401篇 |
耳鼻咽喉 | 3400篇 |
儿科学 | 11534篇 |
妇产科学 | 7099篇 |
基础医学 | 40633篇 |
口腔科学 | 7231篇 |
临床医学 | 22158篇 |
内科学 | 68546篇 |
皮肤病学 | 5465篇 |
神经病学 | 29872篇 |
特种医学 | 13034篇 |
外国民族医学 | 4篇 |
外科学 | 48496篇 |
综合类 | 3186篇 |
一般理论 | 29篇 |
预防医学 | 37993篇 |
眼科学 | 7163篇 |
药学 | 22682篇 |
中国医学 | 1342篇 |
肿瘤学 | 22799篇 |
2023年 | 899篇 |
2022年 | 872篇 |
2021年 | 3141篇 |
2020年 | 1780篇 |
2019年 | 3414篇 |
2018年 | 26689篇 |
2017年 | 20132篇 |
2016年 | 22325篇 |
2015年 | 4541篇 |
2014年 | 5047篇 |
2013年 | 7092篇 |
2012年 | 17436篇 |
2011年 | 31718篇 |
2010年 | 24073篇 |
2009年 | 15549篇 |
2008年 | 28178篇 |
2007年 | 30879篇 |
2006年 | 9816篇 |
2005年 | 11039篇 |
2004年 | 11549篇 |
2003年 | 11977篇 |
2002年 | 9708篇 |
2001年 | 5305篇 |
2000年 | 5983篇 |
1999年 | 4439篇 |
1998年 | 1018篇 |
1992年 | 2320篇 |
1991年 | 2140篇 |
1990年 | 2137篇 |
1989年 | 1812篇 |
1988年 | 1688篇 |
1987年 | 1582篇 |
1986年 | 1608篇 |
1985年 | 1502篇 |
1984年 | 1081篇 |
1983年 | 933篇 |
1979年 | 1234篇 |
1978年 | 827篇 |
1977年 | 793篇 |
1976年 | 756篇 |
1975年 | 893篇 |
1974年 | 1164篇 |
1973年 | 1188篇 |
1972年 | 1129篇 |
1971年 | 1092篇 |
1970年 | 1034篇 |
1969年 | 1116篇 |
1968年 | 1132篇 |
1967年 | 988篇 |
1966年 | 889篇 |
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献
Background
The objective of the study was to evaluate the outcomes of clinically localized prostate cancer treated with prostatectomy versus radiation therapy within the context of a prospective prostate cancer screening study.Patients and Methods
Within the PLCO (Prostate, Lung, Colorectal, and Ovary) trial, patients who were diagnosed with clinically localized prostate cancer and subsequently received treatment with prostatectomy or radiation therapy (with or without hormonal treatment) were included. Univariate and multivariate Cox regression analyses were then performed to determine factors affecting overall and prostate cancer-specific survival. Factors with P < .05 in univariate analysis were included in the multivariate analysis.Results
A total of 3953 patients were included in the current analysis. These included 2044 patients treated with prostatectomy and 1909 patients treated with radiation therapy with or without hormonal treatment. In an adjusted multivariate analysis for factors affecting overall survival, prostatectomy was associated with better overall survival compared with radiation therapy (hazard ratio, 0.548; 95% confidence interval [CI], 0.440- 681; P < .001). Likewise, in an adjusted multivariate analysis for factors affecting prostate cancer-specific survival, prostatectomy was associated with better prostate cancer-specific survival compared with radiation therapy (hazard ratio, 0.485; 95% CI, 0.286- 0.822; P = .007). Similar findings were found with propensity score matching and repeating the same analyses on the post-matching cohort.Conclusion
Prostatectomy seems to predict better overall and prostate cancer-specific survival compared with radiation therapy among patients with clinically localized prostate cancer diagnosed within the PLCO trial. 相似文献Areas covered: This review includes a view of the clinical classification and risk assessment in children suffering from HL. The chemotherapy more commonly employed is revisited. The use of PET/CT to evaluate the disease in order to guide therapy is analyzed. New options of chemotherapy and emerging immunotherapy are also included.
Expert opinion: In order to make the right treatment choice, a proper initial assessment of risk is mandatory. The choice of therapy in these kinds of patients must be done according to the experience of the team, and also, the cost and logistics related to the eligible scheme are very important. If possible, efforts must be made to include PET/CT in guiding therapy and avoiding overtreatment and long-term adverse effects in children. New options in immunotherapy are emerging and must be considered with caution in selected patients. 相似文献